［1］XIA C，DONG X，LI H，et al.Cancer statistics in China and United States，2022：profiles，trends，and determinants［J］.Chin Med J（Engl)，2022,135(5):584-590.
［2］付佳禄，李起，张东，等.《胆囊癌诊断和治疗指南》（2019版）更新解读［J］.肝胆胰外科杂志，2020,32(11):659-663.
FU JL,LI Q,ZHANG D，et al.Guidelines for diagnosis and treatment of gallbladder cancer（2019 edition) updated interpretation［J］.Journal of Hepatobiliary and Pancreatic Surgery，2020,32(11):659-663.
［3］RAWLA P，SUNKARA T，THANDRA KC，et al.Epidemiology of gallbladder cancer［J］.Clin Exp Hepatol，2019,5(2):93-102.
［4］ZHANG L，LU Q，CHANG C.Epigenetics in health and disease［J］.Adv Exp Med Biol，2020,1253:3-55.
［5］MAHMOUD AM，ALI MM.Methyl Donor micronutrients that modify DNA methylation and cancer outcome［J］.Nutrients，2019,11(3):608.
［6］BAKSHI A，BRETZ CL，CAIN TL，et al.Intergenic and intronic DNA hypomethylated regions as putative regulators of imprinted domains［J］.Epigenomics，2018,10(4):445-461.
［7］KLUTSTEIN M，NEJMAN D，GREENFIELD R，et al.DNA methylation in cancer and aging［J］.Cancer Res，2016,76(12):3446-3450.
［8］SPROUL D，KITCHEN RR，NESTOR CE，et al.Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns［J］.Genome Biol，2012,13(10):R84.
［9］SHARMA P，BHUNIA S，POOJARY SS，et al.Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease［J］.Tumour Biol，2016,37(11):14687-14699.
［10］BRAGELMANN J，BARAHONA PC，MARCELAIN K，et al.Epigenome-wide analysis of methylation changes in the sequence of gallstone disease，dysplasia，and gallbladder cancer［J］.Hepatology，2021,73(6):2293-2310.
［11］HUNDAL R，SHAFFER EA.Gallbladder cancer：Epidemiology and outcome［J］.Clin Epidemiol，2014,6:99-109.
［12］LIN B，HONG H，JIANG X，et al.WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival［J］.Gene，2017,622:42-49.
［13］GARCIA P，MANTEROLA C，ARAYA JC，et al.Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions［J］.Mol Carcinog，2009,48(1):79-89.
［14］朝乐孟，李全福.胆囊癌组织甲基化水平的研究［J］.内蒙古医科大学学报，2013,35（2):88-92.
CHAO LM,LI QF.Study on methylation level of gallbladder carcinoma［J］.Journal of Inner Mongolia Medical University,2013,35（2):88-92.
［15］TEKCHAM DS，POOJARY SS，BHUNIA S，et al.Epigenetic regulation of APC in the molecular pathogenesis of gallbladder cancer［J］.Indian J Med Res，2016,143(Supplement):S82-S90.
［16］RIQUELME E，TANG M，BAEZ S，et al.Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma［J］.Cancer Lett，2007,250(1):100-106.
［17］TAKAHASHI T，SHIVAPURKAR N，RIQUELME E，et al.Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis［J］.Clin Cancer Res，2004,10(18 Pt 1):6126-6133.
［18］MISHRA SK，KUMARI N，KRISHNANI N.Molecular pathogenesis of gallbladder cancer：An update［J］.Mutation Research，2019,816-818:111674.
［19］TIWARI PK.Epigenetic biomarkers in gallbladder cancer［J］.Trends in cancer，2020,6(7):540-543.
［20］TEKCHAM DS，GUPTA S，SHRIVASTAV BR，et al.Epigenetic downregulation of PTEN in gallbladder cancer［J］.J Gastrointest Cancer，2017,48(1):110-116.
［21］TOZAWA T，TAMURA G，HONDA T，et al.Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients［J］.Cancer Sci，2004,95(9):736-740.
［22］LEE YM，LEE JY，KIM MJ，et al.Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features［J］.Cancer Sci，2006,97(11):1205-1210.
［23］KAGOHARA LT，SCHUSSEL JL，SUBBANNAYYA T，et al.Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile［J］.Future Oncol，2015,11(2):233-249.
［24］SINGH TD，GUPTA S，SHRIVASTAV BR，et al.Epigenetic profiling of gallbladder cancer and gall stone diseases：Evaluation of role of tumour associated genes［J］.Gene，2016,576(2 Pt 2):743-752.
［25］KATO N，YAMAMOTO H，ADACHI Y，et al.Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids［J］.World J Gastroenterol，2013,19(11):1718-1727.
［26］SATO K，KITAJIMA Y，KOHYA N，et al.Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest［J］.Int J Oncol，2005,26(6):1653-1661.
［27］GONDKAR K，PATEL K，PATIL OG，et al.Dickkopf homolog 3（DKK3) acts as a potential tumor suppressor in gallbladder cancer［J］.Front Oncol，2019,9:1121.
［28］NIMISHA，SALUJA SS，SHARMA AK，et al.Molecular aspects of ABCB1 and ABCG2 in Gallbladder cancer and its clinical relevance［J/OL］.Mol Cell Biochem(2023-01-31)［2023-05-09］.https://doi.org/10.1007/s11010-023-04667-6.
［29］BRANCHI V，SCHAEFER P，SEMAAN A，et al.Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract［J］.Clin Epigenetics，2016,8:133.
［30］BHUNIA S，BARBHUIYA MA，GUPTA S，et al.Epigenetic downregulation of desmin in gall bladder cancer reveals its potential role in disease progression［J］.Indian J Med Res，2020,151(4):311-318.
［31］CAMILA B，CARLOS C，MARIA-JOSE P，et al.Genotoxicity and hypomethylation of LINE-1 induced by electronic cigarettes［J］.Ecotoxicol Environ Saf，2023,256:114900
［32］MOY AP，SHAHID M，FERRONE CR，et al.Microsatellite instability in gallbladder carcinoma［J］.Virchows Arch，2015,466(4):393-402.
［33］JIN L，CAI Q，WANG S，et al.Long noncoding RNA PVT1 promoted gallbladder cancer proliferation by epigenetically suppressing miR-18b-5p via DNA methylation［J］.Cell Death Dis，2020,11(10):871.
［34］SCEUSI EL，LOOSE DS，WRAY CJ.Clinical implications of DNA methylation in hepatocellular carcinoma［J］.HPB（Oxford)，2011,13(6):369-376.
［35］KUMARI S，MISHRA S，ANAND N，et al.Circulating free DNA integrity index and promoter methylation of tumor suppressor gene p16，DAPK and RASSF1A as a biomarker for oropharyngeal squamous cell carcinoma［J］.Pathol Res Pract，2023,246:154489.
［36］KUMARI S，HUSAIN N，AGARWAL A，et al.Diagnostic value of circulating free DNA integrity and global methylation status in gall bladder carcinoma［J］.Pathol Oncol Res，2019,25(3):925-936.
［37］MARTISOVA A，HOLCAKOVA J，IZADI N，et al.DNA methylation in solid tumors：Functions and methods of detection［J］.Int J Mol Sci，2021,22(8):4247.
［38］IGARASHI K，YAMASHITA K，KATOH H，et al.Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1（CDO1) gene in primary gallbladder cancer and gallbladder disease［J］.PLoS One，2017,12(11):e188178.
［39］BHARTI A，KAR AG，SINGH D，et al.Frequent promoter hypermethylation and down regulation of BNIP3：An early event during gallbladder cancer progression［J］.Dig Liver Dis，2022,13:13.
［40］QIU Z，JI J，XU Y，et al.Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes［J］.BMC Med，2022,20(1):64.
［41］SINGH D，BHARTI A，BISWAS D，et al.Frequent downregulation and promoter hypermethylation of DLC1：Relationship with clinical outcome in gallbladder cancer［J］.J Gastrointest Cancer，2022,53(2):237-244.
［42］BAGHEL K，KAZMI HR，CHANDRA A，et al.Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer［J］.Asia Pac J Clin Oncol，2019,15(5):e120-e125.
［43］SKOURTI E，DHILLON P.Cancer epigenetics：Promises and pitfalls for cancer therapy［J］.FEBS J，2022,289(5):1156-1159.
［44］CHIAPPINELLI KB，STRISSEL PL，DESRICHARD A，et al.Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses［J］.Cell，2017,169(2):361.
［45］LI H，CHIAPPINELLI KB，GUZZETTA AA，et al.Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers［J］.Oncotarget，2014,5(3):587-598.
［46］ZHOU Z，LI HQ，LIU F.DNA methyltransferase inhibitors and their therapeutic potential［J］.Curr Top Med Chem，2018,18(28):2448-2457.
［47］HU C，LIU X，ZENG Y，et al.DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor：Mechanism and clinical application［J］.Clin Epigenetics，2021,13(1):166.
［48］ZEIDAN AM，POLLYEA DA，BORATE U，et al.Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia：Retrospective analysis of an electronic medical record database in the United States［J］.Ann Hematol，2023,102(4):749-754.
［49］DAURKIN I，ERUSLANOV E，VIEWEG J，et al.Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine［J］.Cancer Immunol Immunother，2010,59(5):697-706.
［50］XU S，ZHAN M，JIANG C，et al.Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer［J］.Nat Commun，2019,10(1):5492.
［51］XU S，JIANG C，LIN R，et al.Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy［J］.J Exp Clin Cancer Res，2021,40(1):373.
［52］WU M，SHENG L，CHENG M，et al.Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells［J］.Oncogene，2019,38(27):5425-5439.
［53］WANG L，TANG K，LI X，et al.Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly：A case series and review of current literature［J］.J Cancer Res Clin Oncol，2023,149(3):941-950.
［54］KLEIN O，KEE D，NAGRIAL A，et al.Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers：Subgroup analysis of a phase 2 nonrandomized clinical trial［J］.JAMA Oncol，2020,6(9):1405-1409.
［55］SHI C，LI Y，YANG C，et al.Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer：A real-world retrospective study in China［J］.Front Immunol，2022,13:946861.
［56］CHEN X，PAN X，ZHANG W，et al.Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses［J］.Acta Pharm Sin B，2020,10(5):723-733.